BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study

References

• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22.
   Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohn’s Colitis. 2017;11:769–784.
   Google Scholar
• McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021;398:803–816.
   Google Scholar
• Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2022;162:88–108.e9.
   Google Scholar
• Jena A, James D, Singh AK, et al. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;S1542-3565(22):1456–1479.
   Google Scholar
• Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022;21:102927.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
   Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416.
   Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   Google Scholar
• Presidenza del Consiglio dei Ministri. Report Vaccini Anti COVID-19 [Internet]. Available from: https://www.governo.it/it/cscovid19/report-vaccini/.
   Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615–632.
   Google Scholar
• Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring. Nature. 2020;588:377–378.
   Google Scholar
• Doherty J, Fennessy S, Stack R, et al. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther. 2021;54:1110–1123.
   Google Scholar
• Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635–640.
   Google Scholar
• Lev-Tzion R, Focht G, Lujan R, et al. COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation. Clin Gastroenterol Hepatol. 2021;S1542-3565(21):e1263–e1282.
   Google Scholar
• Sung K-Y, Chang T-E, Wang Y-P, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: systemic review and meta-analysis. J Chin Med Assoc. 2021;85:421–430.
   Google Scholar
• World Health Organization. The Global Vaccine Action Plan. 2001–2020, Annex 6: the monitoring and evaluation/accountability framework. Geneva: Switzerland: World Health Organization; 2013.
   Google Scholar
• Rotondo C, Cantatore FP, Fornaro M, et al. Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study. Vaccines (Basel). 2021;9(7):730.
   Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100.
   Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666.
   Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
   Google Scholar
• Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19:173.
   Google Scholar
• Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52:669–681.
   Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11–34.
   Google Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80:1330–1338.
   Google Scholar
• Weaver KN, Zhang X, Dai X, et al. Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID. Inflamm Bowel Dis. 2021; izab302. DOI:10.1093/ibd/izab302.
   Google Scholar
• Wu X, Lin J, Buch H, et al. The COVID-19 vaccination hesitancy among the people with inflammatory bowel disease in china: a questionnaire study. Front Public Health. 2021;9:731578.
   Google Scholar
• Li X, Tong X, Wong ICK, et al. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022; gutjnl-2021-326860. DOI:10.1136/gutjnl-2021-326860.
   Google Scholar
• Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70:1884–1893.
   Google Scholar
• Shehab M, Abu-Farha M, Alrashed F, et al. Immunogenicity of BNT162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study. J Clin Med. 2021;10:5362.
   Google Scholar
• Waldman RA, Grant-Kels JM. Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: a critical appraisal of recent food and drug administration and advisory committee on immunization practices recommendations. J Am Acad Dermatol. 2021;85:1113–1116.
   Google Scholar
• Shehab M, Alrashed F, Alfadhli A, et al. Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies. Vaccines (Basel). 2021;9:1471.
   Google Scholar
• Caldera F, Knutson KL, Saha S, et al. Humoral immunogenicity of mRNA COVID-19 vaccines among patients with inflammatory bowel disease and healthy controls. Am J Gastroenterol. 2022;117:176–179.
   Google Scholar
• Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology. 2022;162(2):454–467.
   Google Scholar